((自动化翻译由路透提供，请见免责声明 )) (更新)
9月20日 - ** Apellis制药公司 股价下跌14.3%至31.46美元，创下自2023年8月以来的最低水平 。
** Apellis称欧洲药品监管机构的人用医药产品委员会$(CHMP)$ 已确认对其实验性药物培西他克普兰持否定意见
** Pegcetacoplan是一种治疗地理性萎缩的试验性药物，地理性萎缩是一种渐进性和不可逆的眼部疾病，是由于病变的生长破坏了负责视力的视网膜细胞而引起的。
** 瑞穗（Mizuho）分析师表示："这一结果对我们来说并不意外，因为我们认为获得积极批准意见的可能性相对较低。
** 瑞穗将 APLS 的预测价格从 42 美元下调至 39 美元，与该股上次收盘价相比有 6% 的上涨空间。
** APLS 于 6 月份寻求重新审查 (link) CHMP 对该药上市申请的负面意见
** 包括本交易日的走势在内，该股 今年累计下跌约 47
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.